Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3352W HIGH $2.61
Volume
408.80 K
Value Traded
1.18 M
Short % Float
17.93%
Days to Cover
27.0
-3.34%Week
-22.44%1 Month
-32.34%3 Month
-15.87%6 Month
-93.86%5 Year
-97.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
221.86 M
EPS (TTM)
-0.43
P/E Ratio
-
Ent. Value
62.84 M
Total Shares
139.54 M
Float Shares
108.35 M
Insiders
22.35%
Institutions
73.32%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IKT Catalyst Timeline
Dated clinical, regulatory and corporate events for Inhibikase Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inhibikase Therapeutics, Inc.
192Total events
5Upcoming
23Tier-1 (high impact)
2018 to 2026Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Inducement stock options granted to two newly-hired non-executive employees
▲Trial InitiationIKT-001FiledTrial
Initiation of 43 clinical sites
Pulmonary Arterial Hypertensionsource ↗
▲Orphan Drug DesignationIKT-001FiledDesignation
FDA grants Orphan Drug Designation to IKT-001 for PAH
Pulmonary Arterial Hypertension (PAH)source ↗
◆Enrollment UpdateIKT-001FiledTrial
Phase 3 IMPROVE-PAH trial actively enrolling patients
Pulmonary Arterial Hypertension (PAH)source ↗
▼ATM ProgramCorporate
Sale of 25,000,000 shares via ATM facility for $50 million gross proceeds
▲Orphan Drug DesignationIKT-001FiledDesignation
FDA granted Orphan Drug Designation
Pulmonary Arterial Hypertensionsource ↗
◆Oral PresentationIKT-001FiledPresentation
Preclinical study data to be presented at American Thoracic Society International Conference (second day)
Pulmonary Arterial Hypertensionsource ↗
◆Oral PresentationIKT-001FiledPresentation
Preclinical study data to be presented at American Thoracic Society International Conference
Pulmonary Arterial Hypertensionsource ↗
▲Oral PresentationIKT-001FiledPresentation
Pre-clinical and Phase 1 data presented at ATS
Pulmonary Arterial Hypertensionsource ↗
▲First Patient DosedIKT-001FiledTrial
First patient enrolled in IMPROVE-PAH Phase 3 study of IKT-001
Pulmonary Arterial Hypertensionsource ↗
▲First Patient DosedIKT-001FiledTrial
First patient enrolled in registrational IMPROVE-PAH study
Pulmonary Arterial Hypertensionsource ↗
▲EMA ValidationIKT-001FiledEx-US Regulatory
EMA confirmation to initiate Phase 3 study
Pulmonary Arterial Hypertensionsource ↗
▲Trial InitiationIKT-001FiledTrial
Phase 3 IMPROVE-PAH study initiated with first sites activated
Pulmonary Arterial Hypertensionsource ↗
◆Enrollment UpdateIKT-001FiledTrial
Actively enrolling patients in IMPROVE-PAH study
Pulmonary Arterial Hypertensionsource ↗
▲Other Regulator MilestoneIKT-001FiledEx-US Regulatory
FAST-EU acceptance for IMPROVE-PAH
Pulmonary Arterial Hypertensionsource ↗
◆Trial InitiationIKT-001FiledTrial
Phase 3 IMPROVE-PAH study initiation expected
Pulmonary Arterial Hypertensionsource ↗
▼Equity OfferingCorporate
Pricing of $100 million public offering of common stock and pre-funded warrants
●Type C MeetingIKT-001FiledFDA Meeting
Type C Meeting request submitted to FDA
Pulmonary Arterial Hypertensionsource ↗
▲FDA Feedback ReceivedIKT-001FiledFDA Meeting
FDA written response from Type C interaction received
Pulmonary Arterial Hypertensionsource ↗
◆Trial InitiationIKT-001FiledTrial
Phase 2b trial of IKT-001 in PAH expected to initiate in Q4 2025
Pulmonary Arterial Hypertension (PAH)source ↗
▲FDA Filing AcceptedIKT-001FiledRegulatory Filing
Regulatory submissions filed in over 20 countries
Pulmonary Arterial Hypertensionsource ↗
▲Type C MeetingIKT-001FiledFDA Meeting
FDA Type C meeting written response received
Pulmonary Arterial Hypertensionsource ↗
◆Interim AnalysisIkT-001ProTrial
Phase 2 interim safety readout anticipated
Pulmonary Arterial Hypertensionsource ↗
◆Trial InitiationIKT-001FiledTrial
Initiation of Phase 2b clinical study of IKT-001 in PAH
Pulmonary Arterial Hypertensionsource ↗
◆Trial InitiationIKT-001FiledTrial
Initiate Phase 2b clinical study of IKT-001 in PAH
pulmonary arterial hypertensionsource ↗
◆Management ChangeCorporate
Amit Munshi appointed Chair of the Board effective February 14, 2025
◆End Of Phase 2 MeetingRisvodetinibFDA Meeting
End of Phase 2 meeting with FDA expected by end of 2024
Parkinson's diseasesource ↗
◆Topline ReadoutRisvodetinibClinical Data
Topline data readout for 201 trial
untreated Parkinson's diseasesource ↗
▼Equity OfferingCorporate
Closed private placement of approximately $110 million with potential aggregate financing up to $275 million
▲Trial InitiationIkT-001ProTrial
Advancement of IkT-001Pro into Phase 2b 702 trial in PAH
Pulmonary Arterial Hypertensionsource ↗
◆Management ChangeCorporate
Appointment of Roberto Bellini, Amit Munshi, Arvind Kush, David Canner to Board; resignation of Gisele Dion and Paul Grint
Past FDA Catalysts and PDUFA Decisions
How IKT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-17 | IKT-001 (prodrug of imatinib mesylate) | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 27%
Micro Cap(rank 178 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IKT-001 Small moleculeNCT07632898 | Pulmonary Arterial Hypertension | Phase 3 | NOT YET_RECRUITING | 970 | Dec 30, 2030 | ||||||
| IkT-001Pro Small moleculeCompletedNCT05623774 | CML | Phase 1 | COMPLETED | 64 | Dec 30, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every IKT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BERMAN DENNIS NDirector | Option | 21,854 21,854 held | $1.26 | 07/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IKT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.8 % (14.3 %) | 22.08 M | 10.88 M |
IKT Institutional Ownership Trends
IKT Short Interest
Shares sold short, counted twice a month.
17.93%
Short % of Float
of tradable shares sold short
19.4M
Shares Sold Short
+4.9% vs prior count
27.0 Very high
Days to Cover
trading days of normal volume to buy every short share back
719.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IKT ranks across every disease it competes in
Competitive Position is a premium feature
See how IKT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIKT News
IKTInhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Inhibikase Therapeutics appointed Dr. Scott Wasserman to its Board of Directors on October 19, 2026. Dr. Wasserman, a cardiologist with over 20 years of experience, previously held leadership roles at Amgen and Kailera Therapeutics. His expertise will support the advancement of the Phase 3 IMPROVE-PAH study for IKT-001, an oral treatment for Pulmonary Arterial Hypertension.
Read more →IKTInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inhibikase Therapeutics has granted stock options to two new non-executive employees as part of its 2026 Inducement Equity Plan. The options, totaling 128,000 shares, have an exercise price of $2.055 and a ten-year term. This move is part of the company's strategy to attract talent while complying with Nasdaq Listing Rule 5635(c)(4). Inhibikase is also advancing its lead product candidate, IKT-001, for treating Pulmonary Arterial Hypertension in a Phase 3 clinical trial.
Read more →IKTInhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its Q2 2026 financial results, highlighting progress in its Phase 3 IMPROVE-PAH study with regulatory approvals in 26 countries. The company presented favorable data for its lead candidate, IKT-001, at the ATS conference, demonstrating potential benefits over existing treatments. Additionally, Inhibikase secured Orphan Drug Designation from the FDA and raised $50 million to support its clinical programs.
Read more →IKT▲ +7.4%on this news
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
Inhibikase Therapeutics announced that the FDA has granted Orphan Drug Designation to IKT-001 for the treatment of Pulmonary Arterial Hypertension (PAH). This designation highlights the significant unmet medical need for the approximately 50,000 PAH patients in the U.S. IKT-001, a prodrug of imatinib mesylate, has shown promising pre-clinical results, including improved pulmonary vascular markers and reduced gastrointestinal toxicity.
Read more →IKT▲ +5.1%on this news
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Inhibikase Therapeutics has successfully sold 25 million shares for $50 million through its at-the-market facility. This capital will support ongoing operations, particularly the Phase 3 IMPROVE-PAH clinical study for its lead product, IKT-001, aimed at treating Pulmonary Arterial Hypertension. The company anticipates that this funding will ensure operational continuity until key data is available.
Read more →IKTInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its financial results for Q1 2026, highlighting the enrollment of the first patient in the IMPROVE-PAH study. The company has secured regulatory approvals in 16 countries, facilitating the initiation of clinical sites. Despite a net loss of $16.4 million, Inhibikase maintains a strong cash position of $170.4 million and plans to present at the upcoming American Thoracic Society Conference.
Read more →IKTInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Inhibikase Therapeutics has enrolled the first patient in its global Phase 3 study, IMPROVE-PAH, evaluating IKT-001 for Pulmonary Arterial Hypertension (PAH). This pivotal trial aims to assess the drug's efficacy in reducing pulmonary vascular resistance and improving patient outcomes. The study features an adaptive design and aims to enroll approximately 486 patients across 180 sites worldwide.
Read more →IKTInhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its financial results for 2025, highlighting a pivotal transition to a Phase 3 clinical study in Pulmonary Arterial Hypertension (PAH). The company has initiated the IMPROVE-PAH study with regulatory approvals in over 20 countries. Despite a net loss of $48.3 million, Inhibikase maintains a strong cash position and has successfully raised $115 million through a public offering.
Read more →IKTInhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics, Inc. has announced the pricing of its public offering, which includes 46,091,739 shares of common stock and pre-funded warrants to purchase an additional 22,873,779 shares. Priced at $1.45 per share, the offering is expected to raise approximately $100 million for the company, with proceeds aimed at advancing its therapeutic portfolio for pulmonary arterial hypertension. The offering is set to close on November 24, 2025, pending customary closing conditions.
Read more →IKTCorporate Overview November 2025 Disclaimer This presentation contains information that may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
Inhibikase Therapeutics, Inc. presented forward-looking statements concerning its drug candidate IKT-001 for pulmonary arterial hypertension (PAH). While the company hopes to address a significant unmet need with IKT-001, uncertainties surrounding clinical trial execution and potential high discontinuation rates of similar therapies pose risks. The company's strong leadership and anticipated initiation of a Phase 3 trial in early 2026 highlight a focused approach to tackling PAH.
Read more →IKTInhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Inhibikase Therapeutics announced that it will advance IKT-001 to a global pivotal Phase 3 clinical study for Pulmonary Arterial Hypertension (PAH), expected to initiate in Q1 2026. This follows a Type C Meeting response from the FDA, allowing the company to implement an adaptive study design. The new study is projected to reduce the timeline for potential FDA approval by three years. IKT-001, a novel pro-drug of imatinib, aims to improve patient outcomes in treating PAH, addressing previous discontinuation issues.
Read more →IKTInhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics has announced a proposed underwritten public offering of its common stock and pre-funded warrants aimed at certain investors. The company is granting underwriters a 30-day option to purchase up to an additional 15% of the total shares offered. This offering is contingent upon market and other conditions, and no guarantees are provided regarding its completion or the terms involved. A prospectus will be filed with the SEC to detail the terms of the offering further.
Read more →IKTInhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its financial results for Q3 2025, highlighting a net loss of $11.9 million and increasing R&D expenses. The company is focusing on advancing IKT-001, a prodrug aimed at treating Pulmonary Arterial Hypertension (PAH), with the intention to begin a Phase 2b clinical trial by the end of 2025. Despite a cash position of $77.3 million, the significant rise in losses and expenses raises concerns about the sustainability of its current strategy.
Read more →IKTInhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Inhibikase Therapeutics has appointed Timothy Pigot as Chief Commercial and Strategy Officer. Pigot brings over 30 years of experience in the pharmaceutical industry, particularly in the pulmonary arterial hypertension (PAH) market. His insights and connections are expected to aid the company's progress as it advances its lead product candidate, IKT-001, toward late-stage clinical trials.
Read more →IKTInhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its financial results for Q2 2025, highlighting advancements in its clinical program for IKT-001, aimed at treating Pulmonary Arterial Hypertension (PAH). The company plans to initiate a Phase 2b clinical study in the latter half of 2025. Despite a strong cash position, the company reported increased net losses and rising R&D expenses compared to the previous year.
Read more →IKTInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics has announced its financial results for the first quarter of 2025, reporting a net loss of $13.7 million as it prepares to advance its treatment IKT-001 into a Phase 2b clinical trial for pulmonary arterial hypertension (PAH) in the second half of the year. The company reported an increase in R&D expenses, largely due to costs associated with its recent acquisition of CorHepta. Despite these challenges, IKT maintains a strong cash position with $93.2 million available to fund its activities moving forward.
Read more →IKTInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Inhibikase Therapeutics has appointed David McIntyre as Chief Financial Officer, effective April 14, 2025. McIntyre brings over two decades of experience in the life sciences sector, having held various executive roles and expertise in financial strategy. The company aims to leverage his skills to advance its lead product, IkT-001, for pulmonary arterial hypertension.
Read more →IKT▲ +11.3%on this newsshared move
CONSULTING AGREEMENT This Agreement is made and entered into as of
Inhibikase Therapeutics, Inc. has entered into a consulting agreement with Garth Lees-Rolfe as of April 11, 2025. The terms include a four-month engagement, during which Lees-Rolfe will provide specified consulting services. The agreement outlines compensation details, establishes Lees-Rolfe's status as an independent contractor, and emphasizes confidentiality and intellectual property rights. Furthermore, it provides for termination conditions and remedies in case of breach.
Read more →About Inhibikase Therapeutics, Inc.
Headquarters1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801
BIOPHARMAWATCH ELITE PLUS
Trade the next IKT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime